S

AN FRANCISCO — When researchers recently showed in a clinical trial that a drug held some promise as a multiple sclerosis treatment, they might have expected interest from biopharma companies fishing for the next addition to their pipelines.

They heard crickets.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.